Corvus Pharmaceuticals (FRA:C17) Accumulated other comprehensive income (loss) : €-0.67 Mil (As of Sep. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Corvus Pharmaceuticals Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Corvus Pharmaceuticals's Accumulated other comprehensive income (loss) for the quarter that ended in Sep. 2024 was €-0.67 Mil.

Corvus Pharmaceuticals's quarterly Accumulated other comprehensive income (loss) declined from Mar. 2024 (€-1.17 Mil) to Jun. 2024 (€-1.26 Mil) but then increased from Jun. 2024 (€-1.26 Mil) to Sep. 2024 (€-0.67 Mil).

Corvus Pharmaceuticals's annual Accumulated other comprehensive income (loss) declined from Dec. 2021 (€1.65 Mil) to Dec. 2022 (€-0.53 Mil) and declined from Dec. 2022 (€-0.53 Mil) to Dec. 2023 (€-0.89 Mil).

Corvus Pharmaceuticals Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Corvus Pharmaceuticals's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corvus Pharmaceuticals Accumulated other comprehensive income (loss) Chart

Corvus Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accumulated other comprehensive income (loss)

Get a 7-Day Free Trial

0.03

1.65

-0.53

-0.89

Corvus Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Accumulated other comprehensive income (loss)	Get a 7-Day Free Trial															-1.35	-0.89	-1.17	-1.26	-0.67

Corvus Pharmaceuticals Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Corvus Pharmaceuticals Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Corvus Pharmaceuticals's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Corvus Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corvus Pharmaceuticals Inc (FRA:C17) » Definitions » Accumulated other comprehensive income (loss)

Comparable Companies

Traded in Other Exchanges

CRVS:USA

Address

863 Mitten Road, Suite 102, Burlingame, CA, USA, 94010

Website

https://www.corvuspharma.com

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Corvus Pharmaceuticals Headlines

No Headlines